CUBRC receives BARDA contract for broad-spectrum antibiotic
CUBRC's biological and medical sciences team will collaborate with Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, to develop, manufacture and clinically evaluate the novel broad-spectrum tetracycline antibiotic. The drug candidate, known as TP-434, will be used for respiratory diseases caused by biothreat and antibiotic-resistant public health pathogens.
The BARDA contract is worth up to $67 million if all options are exercised.
"We are truly thankful for BARDA's confidence in our proposal to develop the next generation of treatments for bacterial infections," Tom McMahon, the president and CEO of CUBRC, said.
Tetraphase discovered and patented TP-434 for further development against biothreat agents such as plague, anthrax and tularemia. The candidate may also have applications against bacterial pathogens such as pneumonia and serious hospital infections.
According to CUBRC, the contract includes a 12-month base period worth $11.5 million. Subsequent options over the next four years could bring the total contract value up to nearly $67 million.
Tetraphase's development pipeline includes potent, novel antibiotics with the potential to treat broad-spectrum and selective-spectrum infections.
CUBRC executes programs in chemical and biological defense, medical biotechnology, public health and safety and hypersonics. The corporation's primary objective is the generation of technological and economic growth.